Content area
Full Text
A 42-year-old man developed lymphocytosis, thrombocytopenia, hepatic toxicity and thyroid dysfunction during an off-label treatment with pembrolizumab for metastatic thymomas. Additionally, he exhibited lack of efficacy during treatment with entecavir for Hepatitis B and mycophenolate mofetil for progressive clinical deterioration.
The man, who had metastatic thymomas, started receiving off-label treatment with pembrolizumab 2 mg/kg, every 21 days, after three lines of standard chemotherapy [route not stated]. Four years prior to pembrolizumab initiation, he was found to have a massive anterior mediastinum mass with numerous pleural nodules during an examination for progressive dyspnoea. At that point, percutaneous pleural biopsy showed CK19+, EMA, CK5/6+ and CK20- versus a...